Tetrahydrocannabivarin (THCV) is like THC’s propyl cannabinoid cousin. Their chemical structure is nearly identical, but the process involved in their creation is slightly different. It differs from THC having a propyl (3-carbon) side chain instead of a pentyl (5-carbon) group on the molecule, which makes it produce very different effects from THC.
It is a minor cannabinoid found in only some strains of cannabis. It acts as an antagonist at the CB1 receptor and a partial agonist at the CB2 receptor.
THCV is a new potential treatment against obesity-associated glucose intolerance. GW Pharmaceuticals is studying THCV (as GWP42004) for type 2 diabetes in addition to metformin.